The Case FOR CJC-1295 + Ipamorelin No DAC: The Research Case for GHRH and GHRP Combination

The CJC-1295 No DAC / Ipamorelin combination is one of the most studied and mechanistically well-characterised stacks in the research peptide community. Unlike many combinations that rest primarily on theoretical receptor pharmacology, this pairing has a documented history in growth hormone secretion research, and the synergistic interaction between GHRH receptor agonists and growth hormone secretagogue receptor agonists is supported by published human data.

The Two-Pathway Architecture of GH Secretion

Growth hormone release from the anterior pituitary is governed by two primary regulatory inputs that operate through distinct receptors and distinct intracellular signalling cascades.

The first is the GHRH pathway. Growth hormone-releasing hormone (GHRH) acts on the GHRH receptor (GHRHR) on somatotroph cells, stimulating adenylyl cyclase, elevating cyclic AMP, and activating protein kinase A. This cascade drives both GH synthesis and the amplitude of pulsatile GH release. CJC-1295 without DAC — also known as Modified GRF(1-29) — is a stabilised synthetic analogue of GHRH's active N-terminal fragment. It retains the core GHRH receptor binding capacity while incorporating amino acid substitutions that improve metabolic stability, extending its effective half-life from the minutes-long duration of native GHRH to approximately 30 minutes.

The second is the GHRP/ghrelin pathway. Growth hormone-releasing peptides act through the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein coupled receptor that signals through calcium-dependent mechanisms to trigger GH release. Ipamorelin is a selective pentapeptide GHRP that activates GHS-R1a with high specificity for GH release and minimal co-activation of cortisol, ACTH, or prolactin — a selectivity profile that distinguishes it from earlier GHRPs such as GHRP-2 and GHRP-6, which produced more pronounced off-target hormonal effects.

Documented Synergy: GHRH + GHRP Is Greater Than the Sum of Parts

The synergistic interaction between GHRH stimulation and GHRP stimulation of GH secretion is not theoretical. It was characterised in published human research in the late 1990s. Studies demonstrated that simultaneous administration of a GHRH analogue and a GHRP produced GH responses that were significantly greater than the additive effects of either compound administered alone — a true pharmacodynamic synergy.

The mechanistic explanation is that the cAMP pathway (GHRH) and the calcium pathway (GHRP/ghrelin) converge on the somatotroph release machinery from different upstream signals. When both pathways are engaged simultaneously, they amplify each other's effect on the magnitude of GH pulse release. The GHRH component also increases the pool of releasable GH within somatotroph secretory granules, providing more substrate for the GHRP-triggered release event.

CJC-1295 (without DAC) combined with Ipamorelin exploits this synergy using two compounds chosen for their clean receptor profiles: CJC-1295 No DAC for GHRH receptor engagement without the prolonged pharmacokinetic tail of the DAC-conjugated version, and Ipamorelin for GHS-R1a engagement without the cortisol and ACTH co-stimulation that other GHRPs produce.

Half-Life Matching and Pulsatile Physiology

The No DAC form of CJC-1295 is specifically preferred for this stack over CJC-1295 with DAC. CJC-1295 with DAC has a half-life of approximately 6 to 8 days, which produces a prolonged blunting of GHRH receptor pulsatility rather than mimicking the episodic GHRH surges that characterise physiological GH regulation. The No DAC version's half-life of approximately 30 minutes more closely mirrors the pulsatile nature of endogenous GHRH release, preserving the frequency-modulated character of normal GH secretion.

Ipamorelin's relatively short half-life aligns with CJC-1295 No DAC's pharmacokinetic window, meaning both compounds reach the pituitary within the same dosing window and can act synergistically during the same GH release event. This pharmacokinetic compatibility — compounds matched to a shared window of activity — is one of the more technically thoughtful aspects of this combination's design.

Status in the Research Community

The CJC-1295 / Ipamorelin combination is one of the longest-standing peptide stacks in research use and is consistently cited in growth hormone research contexts. Pre-blended formulations are available from multiple established research peptide suppliers, and the combination's mechanism is well-represented in the academic and commercial research literature. It remains the benchmark against which newer GH-stimulating combinations are compared.

---

CJC-1295 No DAC and Ipamorelin are research compounds. Neither is approved by the FDA or any equivalent regulatory agency for human use. This article discusses growth hormone secretion research for educational purposes only. Nothing here constitutes medical advice. Do not use any research compound without the guidance of a qualified healthcare professional.